VivoSim to Carry Forward Organovo 3D Bioprinting
Organovo Holdings (Nasdaq: ONVO) has announced its transformation into VivoSim Labs, Inc., marking a strategic evolution of its 3D bioprinting and legacy technology operations. The company's name change will take effect on April 24, 2025, accompanied by a new ticker symbol 'VIVS' on the Nasdaq Capital Market.
The transition requires no action from existing stockholders, and the company will maintain its current CUSIP number (68620A302) and Nasdaq Capital Market listing. This corporate rebranding represents a continuation of Organovo's established bioprinting technology under the new VivoSim identity.
Organovo Holdings (Nasdaq: ONVO) ha annunciato la sua trasformazione in VivoSim Labs, Inc., segnando un'evoluzione strategica delle sue operazioni nel campo della biostampa 3D e delle tecnologie consolidate. Il cambio di nome dell'azienda entrerà in vigore il 24 aprile 2025, accompagnato da un nuovo simbolo di borsa 'VIVS' sul Nasdaq Capital Market.
La transizione non richiede alcuna azione da parte degli azionisti attuali, e l'azienda manterrà il suo attuale numero CUSIP (68620A302) e la quotazione sul Nasdaq Capital Market. Questo rebranding aziendale rappresenta la prosecuzione della tecnologia di biostampa consolidata di Organovo sotto la nuova identità VivoSim.
Organovo Holdings (Nasdaq: ONVO) ha anunciado su transformación en VivoSim Labs, Inc., marcando una evolución estratégica de sus operaciones en bioimpresión 3D y tecnologías heredadas. El cambio de nombre de la compañía entrará en vigor el 24 de abril de 2025, acompañado por un nuevo símbolo bursátil 'VIVS' en el Nasdaq Capital Market.
La transición no requiere ninguna acción por parte de los accionistas actuales, y la empresa mantendrá su número CUSIP actual (68620A302) y su cotización en el Nasdaq Capital Market. Este cambio de marca corporativa representa la continuación de la tecnología de bioimpresión establecida de Organovo bajo la nueva identidad VivoSim.
Organovo Holdings (나스닥: ONVO)가 VivoSim Labs, Inc.로의 전환을 발표하며 3D 바이오프린팅 및 기존 기술 사업의 전략적 진화를 알렸습니다. 회사 명칭 변경은 2025년 4월 24일부터 발효되며, 나스닥 자본시장에 새로운 티커 심볼 'VIVS'로 상장됩니다.
이번 전환은 기존 주주들의 별도 조치를 필요로 하지 않으며, 회사는 현재의 CUSIP 번호(68620A302)와 나스닥 자본시장 상장을 유지할 예정입니다. 이번 기업 브랜드 변경은 Organovo가 구축해온 바이오프린팅 기술을 새로운 VivoSim 정체성 하에 이어가는 것을 의미합니다.
Organovo Holdings (Nasdaq : ONVO) a annoncé sa transformation en VivoSim Labs, Inc., marquant une évolution stratégique de ses activités de bio-impression 3D et de technologies héritées. Le changement de nom de l'entreprise prendra effet le 24 avril 2025, accompagné d'un nouveau symbole boursier 'VIVS' sur le Nasdaq Capital Market.
Cette transition ne nécessite aucune action de la part des actionnaires actuels, et la société conservera son numéro CUSIP actuel (68620A302) ainsi que sa cotation au Nasdaq Capital Market. Ce rebranding d'entreprise représente la poursuite de la technologie de bio-impression établie d'Organovo sous la nouvelle identité VivoSim.
Organovo Holdings (Nasdaq: ONVO) hat seine Umwandlung in VivoSim Labs, Inc. bekannt gegeben, was eine strategische Weiterentwicklung seiner 3D-Bioprinting- und bestehenden Technologieaktivitäten markiert. Die Namensänderung des Unternehmens tritt am 24. April 2025 in Kraft und wird von einem neuen Börsenticker 'VIVS' am Nasdaq Capital Market begleitet.
Der Übergang erfordert keine Maßnahmen der bestehenden Aktionäre, und das Unternehmen behält seine aktuelle CUSIP-Nummer (68620A302) sowie die Notierung am Nasdaq Capital Market bei. Dieses Rebranding stellt eine Fortführung der etablierten Bioprinting-Technologie von Organovo unter der neuen VivoSim-Identität dar.
- Maintains Nasdaq Capital Market listing status
- Continuity of existing 3D bioprinting technology operations
- None.
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”) announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc.
A name change of the Company to VivoSim Labs, Inc. will be effective on April 24, 2025, and the Company’s common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol “VIVS” at market open on April 24, 2025.
No action is required by existing stockholders with respect to the name and ticker symbol change. The Company’s common stock will continue to be listed on the Nasdaq Capital Market and the CUSIP number assigned to the Company's common stock (68620A302) will remain unchanged.
Forward Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 19, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact:
IR@organovo.com
FAQ
When will Organovo (ONVO) change its name to VivoSim Labs and start trading under the new ticker VIVS?
Do Organovo (ONVO) shareholders need to take any action regarding the name and ticker change to VIVS?
What happens to Organovo's 3D bioprinting technology after the transition to VivoSim Labs?
Will the VivoSim Labs (VIVS) stock continue to trade on Nasdaq?
